Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 1, 2012, Pages 47-54

  Chapman, Kent ^a   Seldon, Michael ^b   Richards, Ross ^c  

^a JOHN HUNTER HOSPITAL   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

ADAMTS 13; CD36; thrombotic microangiopathy; thrombotic thrombocytopenic purpura; von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

CONFERENCE PAPER; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEMOSTASIS; MICROTHROMBUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84856998772     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1300951     Document Type: Conference Paper

References (55)

1. Lichtman LA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT. Williams Hematology. 7th ed. Sydney: McGraw-Hill Medical; 2006
2. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int: 2006; 70 1 16 23
3. Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost: 2005; 3 8 1663 1675 (Pubitemid 41716552)
4. George JN. Diagnosis of thrombotic thrombocytopaenia purpura - haemolytic uraemic syndrome in adults. 2010, Available at: www.uptodate.com/contents/ diagnosis-of-thrombotic-thrombo-cytopenic-purpura-hemolytic-uremic- syndromeinadults?source=search-result&search= thombotic+thombocytopaenia+purpura&selectedTitle=1%7E150. Accessed October 12, 2010
5. George JN. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Adv Hematol Oncol: 2005; 3 8 627 632 (Pubitemid 41403804)
6. Desch K, Motto D. Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome? J Am Soc Nephrol: 2007; 18 9 2457 2460 (Pubitemid 47378861)
7. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood: 1996; 87 10 4235 4244
8. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood: 1996; 87 10 4223 4234 (Pubitemid 26152266)
9. Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost: 2007; 33 8 787 797 (Pubitemid 351158447)
10. Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost: 2010; 36 1 71 81
11. Favaloro EJ. Hemolytic uremic syndrome. Preface. Semin Thromb Hemost: 2010; 36 6 573 574
12. Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost: 2010; 36 6 575 585
13. Just S. Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost: 2010; 36 1 82 90
14. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hithero undescribed disease. Proc N Y Pathol Soc.: 1924; 24 21 24
15. Baehr G, Kelmerer P, Schifrin A. Acute febrile anemia and thrombocytopenic purpura with diffuse platelet thrombosis of capillaries and arterioles. Tr A Am Physicians: 1936; 51 43
16. Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses. Blood: 1947; 2 6 542 554
17. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine: 1966; 45 139 160
18. Moake JL, Rudy CK, Troll JH., et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med: 1982; 307 23 1432 1435 (Pubitemid 13234018)
19. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest: 1986; 78 6 1456 1461 (Pubitemid 17219507)
20. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood: 1988; 71 5 1366 1374
21. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood: 2001; 98 6 1662 1666
22. Levy GG, Nichols WC, Lian EC., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature: 2001; 413 6855 488 494 (Pubitemid 32938741)
23. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem: 2001; 276 44 41059 41063
24. Kokame K, Matsumoto M, Soejima K., et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A: 2002; 99 18 11902 11907 (Pubitemid 34994496)
25. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat: 2010; 31 1 11 19
26. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med: 1998; 339 22 1585 1594 (Pubitemid 28536133)
27. Sheiflinger F, Knobl P, Trattner B., et al. Non-neutralising IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood: 2003; 102 9 3241 3243 (Pubitemid 37314762)
28. Key N, Makris M, Oshaunessy D, Lillicrap D. Practical Hemostasis and Thrombosis. 2nd ed. Singapore: Wiley-Blackwell; 2009
29. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood: 2009; 113 21 5049 5057
30. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem: 1998; 67 395 424 (Pubitemid 28411134)
31. McGrath RT, McRae E, Smith OP, ODonnell JS. Platelet von Willebrand factorstructure, function and biological importance. Br J Haematol: 2010; 148 6 834 843
32. Sporn LA, Marder VJ, Wagner DD. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood: 1987; 69 5 1531 1534 (Pubitemid 17085319)
33. Arya M, Anvari B, Romo GM., et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood: 2002; 99 11 3971 3977 (Pubitemid 35332036)
34. Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl: 2009; 112 112 S11 S14
35. Uchida T, Wada H, Mizutani M., et al. Research Project on Genetics of Thrombosis. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood: 2004; 104 7 2081 2083 (Pubitemid 39297860)
36. Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood: 2004; 103 2 627 629 (Pubitemid 38140097)
37. Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost: 2010; 36 1 71 81
38. Zanardelli S, Crawley JTB, Chion CK, Lam JK, Preston RJS, Lane DA. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem: 2006; 281 3 1555 1563
39. Vomund AN, Majerus EM. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem: 2009; 284 45 30925 30932
40. Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood: 2003; 101 3 946 948 (Pubitemid 36139364)
41. Lippi G, Franchini M, Targher G, Poli G, Guidi GC. The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement. Clin Chim Acta: 2007; 381 2 167 170 (Pubitemid 46719152)
42. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood: 2001; 98 9 2730 2735
43. Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost: 1999; 81 1 8 13 (Pubitemid 29041640)
44. Barbot J, Costa E, Guerra M., et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol: 2001; 113 3 649 651 (Pubitemid 32524384)
45. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol: 1994; 88 4 816 825 (Pubitemid 24375798)
46. Schultz DR, Arnold PI, Jy W., et al. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol: 1998; 103 3 849 857 (Pubitemid 28545330)
47. Rock G, Chauhan K, Jamieson GA, Tandon NN. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol: 1994; 88 4 878 880 (Pubitemid 24375807)
48. Rock GA, Clark WF. Mechanism of microthrombosis in HUS. Kidney Int Suppl: 2009; 75 112 S15 S16
49. Nolasco LH, Turner NA, Bernardo A., et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood: 2005; 106 13 4199 4209 (Pubitemid 41775927)
50. a) isoantibody. Transfusion: 2005; 45 803 806 (Pubitemid 40656396)
51. Wakamoto S, Fujihara M, Urushibara N., et al. Heterogeneity of platelet responsiveness to anti-CD36 in plasma associated with adverse transfusion reactions. Vox Sang: 2005; 88 1 41 51
52. Tomiyama Y, Kunicki TJ, Zipf TF, Ford SB, Aster RH. Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression. Blood: 1992; 80 9 2261 2268
53. George JN. ADAMTS13: what it does, how it works, and why its important. Transfusion: 2009; 49 2 196 198
54. Crawley JT, Lam JK, Rance JB, Mollica LR, ODonnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood: 2005; 105 3 1085 1093 (Pubitemid 40170879)
55. Feys HB, Vandeputte N, Palla R., et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost: 2010; 8 9 2053 2062